tetano
Editor, Senior Moderator
Cardiol Ther
. 2022 Apr 15.
doi: 10.1007/s40119-022-00263-9. Online ahead of print.
Thrombotic and Cardiovascular Events and Treatment Patterns Among Patients Hospitalized with COVID-19 in Japan: An Analysis of a Nationwide Medical Claims Database
Naoki Terasaka[SUP] 1 [/SUP], Yukako Matsuo[SUP] 2 [/SUP], Hirohide Kataoka[SUP] 2 [/SUP], Yasuhiko Miyata[SUP] 2 [/SUP], Yoshio Anazawa[SUP] 2 [/SUP]
Affiliations
Abstract
Introduction: Limited data are available regarding the prevalence of thrombotic/cardiovascular disease and treatment patterns for patients with coronavirus disease 2019 (COVID-19) in Japan. In this study we describe patients hospitalized for COVID-19 in Japan.
Methods: This retrospective database study analyzed the Japan Medical Data Vision database (416 acute care hospitals) for patients hospitalized for COVID-19 during the identification period from 1 January 1 to 30 September 2020.
Results: Among 9282 eligible patients, 832 (9%) had developed thrombotic disease including myocardial infarction, ischemic stroke, deep vein thromboembolism and pulmonary embolism. Intriguingly, 171(1.8%) had two thrombotic events and 25 (0.3%) had three or four thrombotic events at the same time. The data also showed that arterial thrombotic events accounted for 77% of total thrombotic events. Anticoagulant and/or antiplatelet medication was provided to 3312 patients. Even with antithrombotic medication, 21.2% of patients suffered from thrombotic diseases.
Conclusions: Patients with COVID-19 could experience thrombotic complications in every blood vessel. Further optimization of medication is crucial for preventing thrombotic complications and improving prognosis.
Keywords: COVID-19; Japanese; Thrombosis.
. 2022 Apr 15.
doi: 10.1007/s40119-022-00263-9. Online ahead of print.
Thrombotic and Cardiovascular Events and Treatment Patterns Among Patients Hospitalized with COVID-19 in Japan: An Analysis of a Nationwide Medical Claims Database
Naoki Terasaka[SUP] 1 [/SUP], Yukako Matsuo[SUP] 2 [/SUP], Hirohide Kataoka[SUP] 2 [/SUP], Yasuhiko Miyata[SUP] 2 [/SUP], Yoshio Anazawa[SUP] 2 [/SUP]
Affiliations
- PMID: 35426621
- DOI: 10.1007/s40119-022-00263-9
Abstract
Introduction: Limited data are available regarding the prevalence of thrombotic/cardiovascular disease and treatment patterns for patients with coronavirus disease 2019 (COVID-19) in Japan. In this study we describe patients hospitalized for COVID-19 in Japan.
Methods: This retrospective database study analyzed the Japan Medical Data Vision database (416 acute care hospitals) for patients hospitalized for COVID-19 during the identification period from 1 January 1 to 30 September 2020.
Results: Among 9282 eligible patients, 832 (9%) had developed thrombotic disease including myocardial infarction, ischemic stroke, deep vein thromboembolism and pulmonary embolism. Intriguingly, 171(1.8%) had two thrombotic events and 25 (0.3%) had three or four thrombotic events at the same time. The data also showed that arterial thrombotic events accounted for 77% of total thrombotic events. Anticoagulant and/or antiplatelet medication was provided to 3312 patients. Even with antithrombotic medication, 21.2% of patients suffered from thrombotic diseases.
Conclusions: Patients with COVID-19 could experience thrombotic complications in every blood vessel. Further optimization of medication is crucial for preventing thrombotic complications and improving prognosis.
Keywords: COVID-19; Japanese; Thrombosis.